Specifics
Relapsed/Refractory setting: Novel agent naïve patients
- BTKi vs PI3Ki vs. Venetoclax as first novel agent?
- In all circumstances, when clinically acceptable, the data support BTKi or Ven before approved PI3Ki.
- No definitive comparative data to support Ven vs. BTKi as first novel agent in novel agent naïve R/R CLL, but limited RWE data is intriguing.
But which BTKi in R/R disease?
- Ibrutinib vs. Acalabrutinib
- Ibrutinib vs. Zanubrutinib
